Data as of 1:38pm ET
| +0.17 / +0.38%|
The 11 analysts offering 12-month price forecasts for Novozymes A/S have a median target of 50.14, with a high estimate of 57.31 and a low estimate of 38.31. The median estimate represents a +11.33% increase from the last price of 45.04.
The current consensus among 11 polled investment analysts is to Outperform stock in Novozymes A/S. This rating has held steady since August, when it was upgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.